| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VEGF-C gene therapy (Herantis Pharma) | LX-1101; Ad-VEGF-C | Phase 2 Clinical | Herantis Pharma | Lymphedema | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Macular Degeneration; Wet Macular Degeneration | Details |